Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Hetero Health Care
28 tablet
Sofosbuvir and Velpatasvir
Keep in cold place
Delivering To:
Overview
Velasof is a combination of two antivirals. It is used in the treatment of chronic hepatitis C virus infection. Velasof (Sofosbuvir and Velpatasvir) stops the multiplication of the virus in the body. Velasof can be taken with or without food. Try to take it at the same time every day. Velasof is not recommended to the patients having a known history of Hepatitis B virus infection due to high risk of adverse reaction.
Hepatitis C
To treat chronic hepatitis C (HCV) infection.
Most side effects of Velasof Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Mood changes
Unusual weakness
Allergic reactions, including skin rash and itching
Shortness of breath
Swelling of the face
Slow heartbeat
Insomnia
Trouble in concentratingTiredness
Diarrhea
Nausea
Sleeping difficulty
Irritability
Loss of appetite
Muscle pain
Sudden cramps
Back pain
Headache
Take the Velasof Tablet exactly as your healthcare provider tells you. Do not alter the dose strength unless your doctor tells you. Seek emergency medical help in case of overdose.
The effect of Velasof 400 mg (recommended dosage) and 1200 mg (three times the recommended dosage) on the QTc interval was demonstrated in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Sofosbuvir (Velasof) does not prolong QTc to any clinically relevant extent, at three times the recommended dose. The effect of Velpatasvir (Velasof) 500 mg (five times the recommended dosage) was demonstrated in an active-controlled (moxifloxacin 400 mg) thorough QT trial. Velpatasvir (Velasof) does not prolong the QTc interval to any clinically relevant extent at five times the recommended dose.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Velasof Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Velasof Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
If you miss a dose of Velasof Tablet, take it as soon as you remember. However, if it is already time for the next dose, please contact your healthcare provider. Do not double the dose to catch up.
Velasof is a combination of two antivirals. It is used in the treatment of chronic hepatitis C virus infection.
Take Velasof exactly as your healthcare provider tells you. Do not crush, chew, or break the tablet. Swallow it as a whole.
There can be certain side effects of Velasof such as fever, diarrhea, nausea, shortness of breath, unusual tiredness, and mood changes. Please consult your healthcare provider if you experience any of these or other side effects.
Store at room temperature (10-30°C). Keep away from direct light, heat, and moisture. Keep out of the reach of children.
This medicine can be taken during breastfeeding if prescribed by a professional healthcare provider (considering the risk factors).
de Avelar, C. R., Nunes, B. V. C., da Silva Sassaki, B., Vasconcelos, M. D. S., de Oliveira, L. P. M., Lyra, A. C., Bueno, A. A. (2023). Efficacy of silymarin in patients with non‑alcoholic fatty liver disease—the SILIVER trial: a randomized controlled clinical trial protocol. Trials, 24(177). https://doi.org/10.1186/s13063-023-07210-6
Imam, S. S., Alshammari, S. O., Alshehri, S., Mahdi, W. A., & Al‑Agamy, M. H. (2024). Formulation of silymarin surface‑modified vesicles: in vitro characterization to cell viability assessment. Saudi Pharmaceutical Journal, 32(6), 102072. https://doi.org/10.1016/j.jsps.2024.102072
Navarro, V. J., Belle, S. H., D’Amato, M., Adfhal, N., Brunt, E. M., Fried, M. W., Harrison, S. (2019). Silymarin in non‑cirrhotics with non‑alcoholic steatohepatitis: a randomized, double‑blind, placebo‑controlled trial. PLoS One, 14(9), e0221683. https://doi.org/10.1371/journal.pone.0221683
